Interv Akut Kardiol. 2022;21(4):219-224 | DOI: 10.36290/kar.2022.031
Transthyretin amyloidosis of the heart: Why should it be kept in mind?
- II. interní klinika - klinika kardiologie a angiologie, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze
In recent years, there has been a significant increase in diagnosed cases of patients with transthyretin amyloidosis (ATTR) of the heart, predominantly with the acquired form of ATTR, also referred to as wild-type ATTR (wtATTR). This is due to the possibility of non-invasive diagnosis of ATTR based on the combination of a clearly positive finding of scintigraphic examination using technetium-labelled bisphosphonates (most often DPD scintigraphy) and a negative result of laboratory tests for AL amyloidosis. It turns out that wtATTR is not a rare cause of heart failure or arrhythmias, particularly of conduction disorders and atrial fibrillation, in elderly patients. The aim of this article is to provide an overview of the clinical manifestations, diagnostic process, and therapeutic options for ATTR, including its specific treatment..
Keywords: amyloidosis, transthyretin, echocardiography, scintigraphy.
Received: October 20, 2022; Accepted: November 23, 2022; Published: December 19, 2022 Show citation
References
- Gertz MA. Cardiac Amyloidosis. Heart Fail Clin. 2022;18(3):479-488.
Go to original source... 
Go to PubMed... - Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: Evolving Diagnosis and Management. A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7-e22. Go to original source... Go to PubMed...
- Gonzalez‑Lopez E, Gallego‑Delgado M, Guzzo‑Merello G, et al. Wild‑type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. Go to original source... Go to PubMed...
- AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11): 1267-1274. Go to original source... Go to PubMed...
- Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879-2887. Go to original source... Go to PubMed...
- Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016 Aug;9(8):e005066. Go to original source... Go to PubMed...
- Maurer MS, Bokhari S, Damy T, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019;12(9):e006075. Go to original source... Go to PubMed...
- Garcia‑Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. Go to original source... Go to PubMed...
- Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyrein Amyloidosis. Circulation. 2016;133(24):2404-12. Go to original source... Go to PubMed...
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. Go to original source... Go to PubMed...
- Rigopoulos AG, Ali M, Abate E, et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail Rev. 2019;24(4):521-533. Go to original source... Go to PubMed...